FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials | Troutman Pepper

For several years, FDA has advanced a policy of increasing diversity in clinical trial populations. During that time, FDA issued broad policy statements, as well as guidance on improved...

Related Keywords

,Drug Administration Safety ,Office Of Minority Health ,Office Of Inspector ,Improve Enrollment ,Underrepresented Racial ,Ethnic Populations ,Draft Guidance ,Clinical Trials ,Affordable Care Act ,Minority Health ,Innovation Act ,Action Plan ,Demographic Subgroup Data ,Draft Guidance Specifies ,Investigational New Drug ,Investigational Device Exemption ,New Drug Application ,Biologics License Application ,Inspector General ,Anti Kickback Statute ,Ethnicity Data ,Ethnicity Specific Data ,Medical Device Clinical Studies ,Clinical Trial Populations ,Eligibility Criteria ,Enrollment Practices ,Trial Designs ,Proposed Arrangement ,